BIO today announced that POET Founder, Chairman and CEO Jeff Broin will receive the 10th annual George Washington Carver Award for Innovation in Industrial Biotechnology. The award will be presented on Monday July 24, 2017, during a morning plenary session of the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.

Washington, DC (May 24, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the announced creation of an Opioid Policy Steering Committee at the Food and Drug Administration (FDA):

Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Trump’s FY 2018 budget proposal.

Mayor Faulconer, Industry Leaders Reveal Latest Data, Including Major Economic Benefits of June BIO 2017 Convention

Washington, DC (May 17, 2017) – Today, the Biotechnology Innovation Organization (BIO) joins with a diverse coalition of stakeholders in endorsing a set of pro-competition, free-market-oriented solutions to lower healthcare costs while increasing patient access and choice to the medicines they need. The proposals, “Prescriptions for Competition, Value and Innovation,” were released by the Council for Affordable Health Coverage (CAHC), of which BIO is a member. The CAHC is a diverse coalition of healthcare stakeholders, including patient and consumer advocacy groups, employers, insurers, pharmacy benefit managers, and biopharmaceutical companies.The proposed solutions focus on five different areas: Increasing Competition: Bringing more generic and branded drugs to the market will increase competition, driving down costs and improving patient and provider choice. Rewarding Value: Reward improved health outcomes and help to lower costs by reforming legal and regulatory barriers that impede private sector value-based contracting for prescription drugs based on outcomes in care. Improving Data Infrastructure and Use: Improving data infrastructure and utilization will increase transparency and improve quality of care, while lowering costs and allowing for more widespread and efficient value and outcomes-based reimbursement contracts. Empowering Consumers: Providing consumers with relevant, easily understood information about their drug choices, including information on their cost-sharing obligations. Preserving What Works: Reject proposals that would undermine functioning markets and the thriving biopharmaceutical innovation ecosystem, or jeopardize patient access or safety.“Last year, BIO released a set of Principles on the Value of Biopharmaceuticals, the first-ever systemic, industry-endorsed set of commitments by research-based biopharmaceutical companies to support comprehensive and sustainable solutions to improve patient access to and affordability of…

Termeer was a key architect in the founding of BIO, a mentor to countless entrepreneurs, executives and researchers, and passionate in his pursuit of innovative patient-centric drug development. Washington, DC (May 15, 2017) – Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish.  As the Boston Globe aptly noted, Termeer had “magnetism and warmth, and a deft ability to harness top talent toward a common goal.”Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health.He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIO’s position at the forefront of key policy and regulatory debates. He was an active member of BIO’s Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIO’s Executive Committee from 1993 to 2000.Following are statements from leadership at the Biotechnology Innovation Organization (BIO):“Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it,” said Jim Greenwood, President and CEO of BIO. “He had a unique ability to inspire the men and women around him. Henri certainly…

Former First Lady of Massachusetts and New York Times best-selling author will speak about the power of resilience in overcoming obstacles, advocating for families and spearheading brain health research

Washington, DC (May 9, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the confirmation of Dr. Scott Gottlieb as Commissioner of the Food and Drug Administration (FDA):

BIO today thanked Sen. Ron Wyden (D-OR) and 21 Senate co-sponsors for proposing a technology neutral tax credit for domestic production of clean transportation fuel. Sen. Wyden’s Clean Energy for America Act proposes a set of long-term energy tax incentives that are available to all technologies and promote performance based clean energy in the United States. BIO supports Sen. Wyden’s efforts to ensure that any tax reform package Congress considers includes incentives that promote the development and production of advanced and cellulosic biofuels.